Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P von Hoegen

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Immunology Letters|September 1, 1995
Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytesP von Hoegen
Advanced Drug Delivery Reviews|August 23, 2001
Synthetic biomimetic supra molecular Biovector (SMBV) particles for nasal vaccine deliveryP von Hoegen
European Journal of Immunology|August 1, 1988
Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral responseP Von Hoegen, E Weber, V Schirrmacher
International Journal of Cancer|July 15, 1994
Scattered micrometastases visualized at the single-cell level: detection and re-isolation of lacZ-labeled metastasized lymphoma cellsA Krüger, V Schirrmacher, P von Hoegen
International Journal of Cancer|November 15, 1986
Immunoresistant metastatic tumor variants can re-express their tumor antigen after treatment with DNA methylation-inhibiting agentsP Altevogt, P von Hoegen, V Schirrmacher
Cellular Immunology|October 15, 1987
New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cellsP von Hoegen, P Altevogt, V Schirrmacher
Cancer Immunology, Immunotherapy : CII|March 7, 1998
Superiority of the ear pinna over a subcutaneous tumour inoculation site for induction of a Th1-type cytokine responseK Jurianz, P von Hoegen, V Schirrmacher
International Journal of Oncology|June 22, 1999
Immunological and molecular characterization of an aggressive murine lymphoma variant: modulation in vitro and in vivoK Jurianz, P von Hoegen, V Schirrmacher
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperationH Schild, P von Hoegen, V Schirrmacher
Cellular Immunology|March 1, 1990
Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/betaP von Hoegen, R Zawatzky, V Schirrmacher
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Immunology Letters|September 1, 1995
Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytesP von Hoegen
Advanced Drug Delivery Reviews|August 23, 2001
Synthetic biomimetic supra molecular Biovector (SMBV) particles for nasal vaccine deliveryP von Hoegen
European Journal of Immunology|August 1, 1988
Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral responseP Von Hoegen, E Weber, V Schirrmacher
International Journal of Cancer|July 15, 1994
Scattered micrometastases visualized at the single-cell level: detection and re-isolation of lacZ-labeled metastasized lymphoma cellsA Krüger, V Schirrmacher, P von Hoegen
International Journal of Cancer|November 15, 1986
Immunoresistant metastatic tumor variants can re-express their tumor antigen after treatment with DNA methylation-inhibiting agentsP Altevogt, P von Hoegen, V Schirrmacher
Cellular Immunology|October 15, 1987
New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cellsP von Hoegen, P Altevogt, V Schirrmacher
Cancer Immunology, Immunotherapy : CII|March 7, 1998
Superiority of the ear pinna over a subcutaneous tumour inoculation site for induction of a Th1-type cytokine responseK Jurianz, P von Hoegen, V Schirrmacher
International Journal of Oncology|June 22, 1999
Immunological and molecular characterization of an aggressive murine lymphoma variant: modulation in vitro and in vivoK Jurianz, P von Hoegen, V Schirrmacher
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperationH Schild, P von Hoegen, V Schirrmacher
Cellular Immunology|March 1, 1990
Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/betaP von Hoegen, R Zawatzky, V Schirrmacher
Pageof 4